Fig. 2From: Clinical outcomes in patients relapsed/refractory after ≥2 prior lines of therapy for follicular lymphoma: a systematic literature review and meta-analysisMeta-analysis of response outcomes. BsMAb, bispecific monoclonal antibody; CI, confidence interval; EZH2. Enhancer of zeste homolog 2; PI3k-d Phosphoinositide 3-kinase deltaBack to article page